Unnamed: 0,title,date,stock,sentiment
1005729.0,Progenics to Present Results from the Phase 3 CONDOR Trial of PyLâ„¢ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program,2020-05-18 08:34:00-04:00,PGNX,negative
1005730.0,"Progenics Pharmaceuticals Q1 EPS $(0.190) Beats $(0.220) Estimate, Sales $6.200M Miss $7.900M Estimate",2020-05-07 08:16:00-04:00,PGNX,negative
1005731.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,PGNX,negative
1005732.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,PGNX,neutral
1005733.0,"Lantheus, Progenics Pharma Report Support Deal With Velan Capital Related To Merger",2020-04-14 09:20:00-04:00,PGNX,positive
1005734.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,PGNX,positive
1005735.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,PGNX,neutral
1005736.0,Progenics Pharma Q4 EPS $(0.13) vs $(0.17) In Same Qtr. Last Year,2020-03-13 08:32:00-04:00,PGNX,neutral
1005737.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,PGNX,negative
1005738.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,PGNX,negative
1005739.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,PGNX,negative
1005740.0,95 Biggest Movers From Yesterday,2020-02-21 05:12:00-05:00,PGNX,neutral
1005741.0,"Lantheus, Progenics Pharma Report Amended Ratio For Deal: Lantheus Stock Term Raised From 0.2502 Lantheus Share To 0.31",2020-02-20 11:34:00-05:00,PGNX,positive
1005742.0,Progenics Pharmaceuticals Provides Update On Reconstituted Board's Ongoing Strategic Review,2020-01-21 16:17:00-05:00,PGNX,neutral
1005743.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,PGNX,negative
1005744.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,PGNX,neutral
1005745.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-23 12:19:00-05:00,PGNX,neutral
1005746.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,PGNX,neutral
1005747.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-23 07:50:00-05:00,PGNX,neutral
1005748.0,20 Stocks Moving in Monday's Pre-Market Session,2019-12-23 07:44:00-05:00,PGNX,neutral
1005749.0,Progenics Pharmaceuticals shares are trading higher after the company announced the Phase 3 CONDOR trial on PyL in prostate cancer met the primary endpoint.,2019-12-23 07:36:00-05:00,PGNX,negative
1005750.0,Progenics' Phase 3 CONDOR Trial of PyL Met its Primary Endpoint,2019-12-23 07:01:00-05:00,PGNX,neutral
1005751.0,"Progenics Halted, News Pending",2019-12-23 06:56:00-05:00,PGNX,neutral
1005752.0,Progenics Pharma Names David Mims Interim CEO,2019-11-21 16:09:00-05:00,PGNX,neutral
1005753.0,Progenics Pharmaceuticals shares are trading lower. The company announced it has delivered written consents from the holders of more than 55% of the company's outstanding shares to remove CEO Mark Baker and Nicole Williams from the Board of Directors.,2019-11-11 11:36:00-05:00,PGNX,positive
1005754.0,Velan Receives Requisite Number Of Written Consents To Reconstitute Majority Of Progenics Board,2019-11-08 14:25:00-05:00,PGNX,positive
1005755.0,"Progenics Pharmaceuticals Q3 EPS $(0.22) Down From $(0.01) YoY, Sales $5.6M Up From $5.317M YoY",2019-11-07 09:51:00-05:00,PGNX,neutral
1005756.0,Velan Capital Highlights Glass Lewis Recommendation Progenics Shareholders Vote On Green Consent Card For Velan Nominees,2019-11-04 08:25:00-05:00,PGNX,positive
1005757.0,Progenics Issues Shareholder Letter Telling Shareholders To Reject Velan Capital's Board Nominees,2019-11-04 08:14:00-05:00,PGNX,negative
1005758.0,Progenics Reports Strongly Agrees With ISS Recommendation Valen Group Shot Not Get Majority Control Of Board,2019-10-28 14:02:00-04:00,PGNX,positive
1005759.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,PGNX,neutral
1005760.0,Velan Capital Issues Press Release Highlighting Response To 'Misleading Communications' From Progenics,2019-10-23 17:04:00-04:00,PGNX,negative
1005761.0,"Progenics Sends Letter To Shareholders, Highlights Added Concerns About Velan Capital",2019-10-23 09:55:00-04:00,PGNX,neutral
1005762.0,"Velan Sends Progenics Pharmaceuticals Shareholders With New Plan And Independent Board Nominees, Criticizes Proposed Lantheus Transaction",2019-10-22 09:14:00-04:00,PGNX,negative
1005763.0,"Progenics Pharma Board Sends Letter To Shareholders, Urges Vote On WHITE Proxy Card",2019-10-21 08:48:00-04:00,PGNX,neutral
1005764.0,35 Stocks Moving In Thursday's Mid-Day Session,2019-10-10 12:18:00-04:00,PGNX,neutral
1005765.0,Progenics Reports Will Send Letter To Shareholders Highlighting Belief In Value Which Will Be Created By Deal With Lantheus And Uncertainty Surrounding Velan Capital's Plan,2019-10-09 16:32:00-04:00,PGNX,positive
1005766.0,Progenics Pharmaceuticals shares are trading lower. The stock is up over 8% in the past week and traders may potentially be taking profits.,2019-10-07 09:23:00-04:00,PGNX,positive
1005767.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-10-07 08:09:00-04:00,PGNX,neutral
1005768.0,46 Biggest Movers From Yesterday,2019-10-03 05:05:00-04:00,PGNX,neutral
1005769.0,Lantheus To Acquire Progenics Pharma In All-Stock Deal,2019-10-02 15:12:00-04:00,PGNX,neutral
1005770.0,Velan Comments On Announced Sale Of Progenics To Lantheus,2019-10-02 13:34:00-04:00,PGNX,neutral
1005771.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-02 08:54:00-04:00,PGNX,neutral
1005772.0,23 Stocks Moving in Wednesday's Pre-Market Session,2019-10-02 07:57:00-04:00,PGNX,neutral
1005773.0,Lantheus To Acquire Progenics To Form Precision Diagnostics Imaging And Therapeutics Company; Progenics Shareholders To Receive 0.2502 Shares Of Lantheus Common Stock For Each Progenics Share,2019-10-02 07:47:00-04:00,PGNX,positive
1005774.0,Progenics Pharmaceuticals Shares Resume Trade,2019-10-02 07:45:00-04:00,PGNX,positive
1005775.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,PGNX,neutral
1005776.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,PGNX,negative
1005777.0,Progenics Says Velan Capital Has Filed To Attempt To Gain Five Seats On Board,2019-09-18 17:02:00-04:00,PGNX,positive
1005778.0,"Altiva Management Says Continued To Engage With Progenics Pharmaceuticals With Hope Of Reaching A Mutual Resolution, Including Appointment Of New Directors; Progenics  Board Has Been Unreceptive To Its Efforts To Reach A Resolution",2019-08-26 17:08:00-04:00,PGNX,positive
1005779.0,66 Biggest Movers From Yesterday,2019-08-23 05:05:00-04:00,PGNX,neutral
1005780.0,Stocks That Hit 52-Week Lows On Tuesday,2019-08-20 10:55:00-04:00,PGNX,negative
1005781.0,"The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission",2019-08-16 07:33:00-04:00,PGNX,negative
1005782.0,76 Biggest Movers From Yesterday,2019-08-13 04:57:00-04:00,PGNX,neutral
1005783.0,"Progenics Pharmaceuticals Q2 EPS $(0.23) Misses $(0.19) Estimate, Sales $9.966M Beat $6.66M Estimate",2019-08-09 07:39:00-04:00,PGNX,negative
1005784.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,PGNX,negative
1005785.0,"Progenics Pharmaceuticals Announces Board Accepts Resignations Of Directors Peter J. Crowley And Michael D. Kishbauch, Effective October 17, 2019",2019-08-08 08:35:00-04:00,PGNX,positive
1005786.0,Progenics Pharmaceuticals Announces That The Centers For Medicare & Medicaid Services Has Approved Add-On Payment For AZEDRA,2019-08-06 08:35:00-04:00,PGNX,positive
1005787.0,Progenics Pharmaceuticals Completes Enrollment In Pivotal Phase 3 CONDOR Study Of PyL For Detection Of Prostate Cancer,2019-08-05 08:31:00-04:00,PGNX,negative
1005788.0,"Benzinga's Top Upgrades, Downgrades For July 30, 2019",2019-07-30 09:59:00-04:00,PGNX,positive
1005789.0,"Brookline Capital Initiates Coverage On Progenics Pharmaceuticals with Buy Rating, Announces $10 Price Target",2019-07-30 06:48:00-04:00,PGNX,neutral
1005790.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,PGNX,neutral
1005791.0,"Progenics Pharma Highlights Collaboration With Veterans Affairs On AI Research Program For Medical Image Analysis, No Terms Disclosed",2019-07-25 08:42:00-04:00,PGNX,negative
1005792.0,"Bausch Health,  Progenics Announce Court Upholds Validity and Determined Actavis' Infringement of Patent Protecting RELISTOR Tablets",2019-07-17 19:46:00-04:00,PGNX,negative
1005793.0,Seeing Social Media Mention Of Progenics Prevailing In Relistor Patent Litigation,2019-07-17 15:14:00-04:00,PGNX,negative
1005794.0,"The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO",2019-06-28 07:32:00-04:00,PGNX,negative
1005795.0,Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital,2019-06-28 04:22:00-04:00,PGNX,positive
1005796.0,Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors,2019-06-28 04:20:00-04:00,PGNX,positive
1005797.0,Velan Capital Urgers Shareholders To Vote Against Re Election Of Certain Board Nominees,2019-06-25 08:31:00-04:00,PGNX,positive
1005798.0,"Progenics Says Independent Readers Using Co.'s PSMA AI Demonstrated Statistically Significant Improvement Of Accuracy, Speed, And Reproducibility Over Readers Without PSMA AI",2019-06-24 08:34:00-04:00,PGNX,positive
1005799.0,Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan's Latest Inaccurate Claims,2019-06-24 08:06:00-04:00,PGNX,neutral
1005800.0,Progenics Pharmaceuticals To Initiate Basket Trial By Year End To Support  Expanded Label For AZEDRA In Multiple MIBG Avid Neuroendocrine Tumors,2019-06-20 08:34:00-04:00,PGNX,positive
1005801.0,Progenics Sends Letter To Shareholders Urging Vote For All Co. Directors On WHITE Proxy Card,2019-06-19 08:35:00-04:00,PGNX,neutral
1005802.0,Progenics Pharmaceuticals Announces Agreement With FUJIFILM Toyama Chemical Co. For Automated Bone Scan Index (aBSI) Product In Japan,2019-06-18 09:06:00-04:00,PGNX,positive
1005803.0,Progenics Pharma Shareholder Velan Capital Makes a Statement to Shareholders,2019-06-17 08:33:00-04:00,PGNX,neutral
1005804.0,"Progenics To Sends Letter To Shareholders, Urges Vote For WHITE Proxy Card",2019-06-13 17:01:00-04:00,PGNX,neutral
1005805.0,Progenics Pharma Reports Dosing Of First Patient With Phase 2 Study Of 1095 Radiotherapy for Treatment Of Metastatic Prostate Cancer,2019-06-13 08:33:00-04:00,PGNX,negative
1005806.0,"Progenics Shareholder, Velan Capital, Sends Letter To Shareholders Criticizing Board For Dilution, Urges Shareholders To Vote Against Re-Election Of Board Members",2019-06-11 08:35:00-04:00,PGNX,negative
1005807.0,"Progenics Shareholder, Velan Capital, Responds To 'Misleading' Statements From Co.; Expresses Concern With 'Misalignment' Of Interests With Progenics Stockholders",2019-06-04 08:43:00-04:00,PGNX,positive
1005808.0,Progenics Highlights Presentation Of Updated Survival Data For AZEDRA In Advanced Pheochromocytoma And Paraganglioma; Patients Treated With AZEDRA Show Overall Survival Of 73.1% At Two Years And 44.2% At Four Years,2019-06-03 08:34:00-04:00,PGNX,positive
1005809.0,Progenics Pharmaceuticals And ROTOP Pharmaka GmbH Announce European Collaboration For Prostate Cancer Imaging Agent 1404,2019-05-14 08:34:00-04:00,PGNX,negative
1005810.0,"Progenics Pharmaceuticals Q1 EPS $(0.22) Misses $(0.19) Estimate, Sales $4.281M Beat $4.15M Estimate",2019-05-09 07:45:00-04:00,PGNX,negative
1005811.0,Progenics Pharmaceuticals Comments On Velan Capital's Preliminary Proxy Statement,2019-05-07 17:06:00-04:00,PGNX,neutral
1005812.0,Progenics Pharma Issues Statement Related To Velan Capital: Urges Shareholder To Vote For WHITE Proxy Card,2019-05-06 17:21:00-04:00,PGNX,neutral
1005813.0,Velan Capital Sends Letter To Progenics Pharma Board,2019-05-06 08:35:00-04:00,PGNX,neutral
1005814.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,PGNX,neutral
1005815.0,Progenics Highlights Publication Of Analysis Of PyL (18F-DCFPyL) In A Medical Journal,2019-04-24 08:34:00-04:00,PGNX,neutral
1005816.0,Progenics Pharma 13D Filing From Altiva Mgmt. Shows 6% Stake,2019-04-05 09:07:00-04:00,PGNX,neutral
1005817.0,"Progenics Pharmaceuticals Q4 EPS $(0.17) Misses $(0.11) Estimate, Sales $3.238M Down From $3.889M YoY",2019-03-14 07:51:00-04:00,PGNX,negative
1005818.0,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering",2019-03-14 07:47:00-04:00,PGNX,neutral
1005819.0,Progenics Reports Has Asserted Ownership Of Global Composition Of Matter Patent Filings Related To PSMA-617,2019-03-14 07:43:00-04:00,PGNX,neutral
1005820.0,Progenics Pharmaceuticals Announces Presentation Of Safety Data For AZEDRA At 2019 Endocrine Society (ENDO) Annual Meeting,2019-03-11 08:37:00-04:00,PGNX,positive
1005821.0,Progenics Acquires Azedra Radiopharmaceutical Manufacturing Facility For $8M,2019-02-11 08:33:00-05:00,PGNX,neutral
1005822.0,"Curium, Progenics Announce European Collaboration for Prostate Cancer Imaging Agent PyL",2019-01-03 04:08:00-05:00,PGNX,negative
1005823.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,PGNX,positive
1005824.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,PGNX,positive
1005825.0,52 Biggest Movers From Yesterday,2018-12-13 04:54:00-05:00,PGNX,neutral
1005826.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-12-12 12:33:00-05:00,PGNX,neutral
1005827.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,PGNX,neutral
1005828.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,PGNX,negative
1005829.0,"Credit Suisse Initiates Coverage On Progenics Pharmaceuticals with Outperform Rating, Announces $6.50 Price Target",2018-12-07 08:31:00-05:00,PGNX,positive
1005830.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,PGNX,negative
1005831.0,"Progenics Doses First Patient In Pivotal Phase 3 Study Of PyL, PSMA PET Imaging Agent, For The Detection Of Prostate Cancer",2018-12-03 08:38:00-05:00,PGNX,negative
1005832.0,"Progenics Pharma Says Will Present Safety, Tolerability Data From Pooled Analysis Of 4 Open-Label Phase 1, 2 Studies Of AZEDRA In Patients With Iobenguane Scan Positive Cancers At Radiological Society of North America Nov. 26, 2018",2018-11-19 16:37:00-05:00,PGNX,positive
1005833.0,"Progenics Pharmaceuticals Inc. Q3 EPS $(0.30) Misses $(0.18) Estimate, Sales $5.32M Beat $4.12M Estimate",2018-11-08 07:50:00-05:00,PGNX,negative
1005834.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,PGNX,negative
1005835.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,PGNX,neutral
1005836.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,PGNX,negative
1005837.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,PGNX,negative
1005838.0,Progenics Pharma Reports Advancement Of I-131 1095 For Treatment Of Metastatic Prostate Cancer Into Phase 2 Clinical Study,2018-10-11 16:01:00-04:00,PGNX,negative
1005839.0,Progenics On Positive Prostate Cancer Imaging Data: 'These Are Highly Encouraging Results',2018-10-05 09:52:00-04:00,PGNX,positive
1005840.0,"Progenics Shares Resume Trade, Spike To High Of $6.50, Up 6%, Pullback From High, Now Up 0.5%",2018-10-05 08:04:00-04:00,PGNX,positive
1005841.0,Progenics Pharma Shares To Resume Trade At 8 a.m. EDT,2018-10-05 07:40:00-04:00,PGNX,positive
1005842.0,"UPDATE: Progenics Says 18F-DCFPyL 'Very Well' Tolerated, 7% Of Subjects Experienced At Least One Treatment-Related Adverse Event, But No Serious Adverse Events",2018-10-05 07:33:00-04:00,PGNX,negative
1005843.0,"Progenics Pharma Reports Results Of Phase 2/3 Trial Of PyL For Detection Of Prostate Cancer: First Co-Primary Endpoint Was Met, Second Co-Primary Endpoint Was Not Met",2018-10-05 07:32:00-04:00,PGNX,negative
1005844.0,Progenics Pharma Shares Halted News Pending,2018-10-05 07:25:00-04:00,PGNX,positive
1005845.0,24 Stocks Moving In Friday's Pre-Market Session,2018-09-14 08:01:00-04:00,PGNX,neutral
1005846.0,46 Biggest Movers From Yesterday,2018-09-14 04:40:00-04:00,PGNX,neutral
1005847.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-09-13 13:12:00-04:00,PGNX,neutral
1005848.0,Mid-Day Market Update: Crude Oil Down Over 2%; Progenics Pharmaceuticals Shares Plunge,2018-09-13 12:17:00-04:00,PGNX,negative
1005849.0,Mid-Morning Market Update: Markets Open Higher; Kroger Sales Miss Views,2018-09-13 10:13:00-04:00,PGNX,negative
1005850.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,PGNX,neutral
1005851.0,18 Stocks Moving In Thursday's Pre-Market Session,2018-09-13 08:19:00-04:00,PGNX,neutral
1005852.0,10 Stocks Moving In Wednesday's After-Hours Session,2018-09-12 18:00:00-04:00,PGNX,neutral
1005853.0,"UPDATE: Progenics Pharmaceuticals CEO Says Top Line Phase 3 Results Of 1404 Are Inconsistent With Phase 2 Data, Co. Conducting Thorough Analysis To Understand Outcome",2018-09-12 17:13:00-04:00,PGNX,positive
1005854.0,Progenics Pharmaceuticals shares are down 17.7% after hours after Phase 3 data for cancer imaging agent 1404 did not meet co-primary endpoint of sensitivity.,2018-09-12 17:11:00-04:00,PGNX,negative
1005855.0,"Progenics Pharma Shares Resume Trade, Down 11.2%",2018-09-12 16:30:00-04:00,PGNX,positive
1005856.0,Progenics Shares To Resume Trade At 4:30 p.m. EDT,2018-09-12 16:09:00-04:00,PGNX,positive
1005857.0,Progenics Pharma Shares Halted News Pending,2018-09-12 16:02:00-04:00,PGNX,positive
1005858.0,"Progenics Pharmaceuticals Reports Top Line Phase 3 Data For Prostate Cancer Imaging Agent 1404 Met Co-Primary Endpoint Of Specificity, Did Not Meet Endpoint Of Sensitivity",2018-09-12 16:02:00-04:00,PGNX,negative
1005859.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,PGNX,neutral
1005860.0,85 Biggest Movers From Yesterday,2018-08-09 05:15:00-04:00,PGNX,neutral
1005861.0,68 Stocks Moving In Wednesday's Mid-Day Session,2018-08-08 12:30:00-04:00,PGNX,neutral
1005862.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,PGNX,positive
1005863.0,40 Stocks Moving In Wednesday's Pre-Market Session,2018-08-08 08:08:00-04:00,PGNX,neutral
1005864.0,Progenics Pharmaceuticals Prices 9.09M Share Offering of Common Stock @$8.25/Share,2018-08-08 04:03:00-04:00,PGNX,positive
1005865.0,Progenics Pharmaceuticals Reports Proposed Public Offering of Common Stock,2018-08-07 16:02:00-04:00,PGNX,neutral
1005866.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,PGNX,neutral
1005867.0,"Stocks Which Set New 52-Week Highs Friday, August 3rd",2018-08-06 13:02:00-04:00,PGNX,neutral
1005868.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-08-02 08:05:00-04:00,PGNX,neutral
1005869.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,PGNX,negative
1005870.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Jul. 31, 2018",2018-07-31 17:56:00-04:00,PGNX,positive
1005871.0,"Progenics Pharmaceuticals Q2 EPS $(0.20) Up From $(0.24) YoY, Sales $3.88M Up From $2.765M YoY",2018-07-31 16:45:00-04:00,PGNX,neutral
1005872.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-31 09:01:00-04:00,PGNX,neutral
1005873.0,"Progenics Pharma Shares Resume Trade, Up 15.6%",2018-07-31 07:13:00-04:00,PGNX,positive
1005874.0,50 Biggest Movers From Yesterday,2018-07-31 04:23:00-04:00,PGNX,neutral
1005875.0,"Progenics Pharmaceuticals Announces FDA Approval for AZEDRA to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma",2018-07-31 03:45:00-04:00,PGNX,positive
1005876.0,Press Release Confirms Progenics Pharma Receives FDA Approval For Azedra,2018-07-30 15:36:00-04:00,PGNX,positive
1005877.0,"Progenix Pharma Halt Code Changed From Volatility To T1, News Pending",2018-07-30 15:12:00-04:00,PGNX,neutral
1005878.0,"UPDATE: FDA.gov Site Appears To Display Approval For Progenics Pharma's Azedra, For Which The Co. Had a PDUFA Date Set for Today",2018-07-30 15:07:00-04:00,PGNX,positive
1005880.0,"The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO",2018-07-30 13:46:00-04:00,PGNX,neutral
1005881.0,REMINDER: Progenix Pharma Has FDA PDUFA Date Today For Azedra,2018-07-30 06:13:00-04:00,PGNX,neutral
1005882.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,PGNX,neutral
1005883.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2018-06-30 18:05:00-04:00,PGNX,neutral
1005884.0,Progenics Pharma Closes Enrollment Of Phase 2/3 Trial Of PSMA-Targeted PET/CT Imaging Agent PyL In Prostate Cancer,2018-06-26 08:33:00-04:00,PGNX,negative
1005885.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-06-26 08:00:00-04:00,PGNX,neutral
1005886.0,These 5 Stocks Are In Various Phases Of Downtrends Right Now,2018-06-22 11:21:00-04:00,PGNX,neutral
1005887.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,PGNX,neutral
1005888.0,8-K From Progenics Pharma Reports On May 25th Co. Entered a Settlement With Valeant and Salix Regarding Patent Infringement Case,2018-05-31 17:34:00-04:00,PGNX,negative
1005889.0,Progenics Pharmaceuticals Q1 EPS $(0.19) Beats $(0.21) Estimate,2018-05-09 07:32:00-04:00,PGNX,neutral
1005890.0,42 Biggest Movers From Friday,2018-03-26 05:13:00-04:00,PGNX,neutral
1005891.0,30 Stocks Moving In Friday's Mid-Day Session,2018-03-23 13:10:00-04:00,PGNX,neutral
1005892.0,25 Stocks Moving In Friday's Pre-Market Session,2018-03-23 08:09:00-04:00,PGNX,neutral
1005893.0,Progenics Pharmaceuticals Down 15-16% After FDA Extended Review Of New Drug Application For AZEDRA By Three Months,2018-03-22 16:35:00-04:00,PGNX,neutral
1005894.0,"Progenics Pharma Reports 3-Month Extension Of PDUFA Date For AZEDRA To Jul. 30, 2018",2018-03-22 16:18:00-04:00,PGNX,neutral
1005895.0,"Progenics Shares Up 3.8%, Stock Has Risen 17% Since Co. Announced Q4 Results March 8th; Co. Reported EPS $(0.04) vs $(0.10) In Same Qtr. Last Year, Sales $3.889M vs $4.652M YoY",2018-03-13 13:17:00-04:00,PGNX,positive
1005896.0,"Autodesk, SCANA, And 3 Other Stocks With Clear Trading Opportunities This Week",2018-03-13 12:18:00-04:00,PGNX,positive
1005897.0,56 Biggest Movers From Yesterday,2018-03-09 04:51:00-05:00,PGNX,neutral
1005898.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-03-08 12:31:00-05:00,PGNX,neutral
1005899.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,PGNX,neutral
1005900.0,Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404,2018-01-02 08:34:00-05:00,PGNX,neutral
1005901.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-01-02 08:11:00-05:00,PGNX,neutral
1005902.0,26 Stocks Moving In Friday's Mid-Day Session,2017-12-29 12:36:00-05:00,PGNX,neutral
1005903.0,Mid-Day Market Update: ADTRAN Drops On Weak Q4 Guidance; Atara Biotherapeutics Shares Spike Higher,2017-12-29 12:15:00-05:00,PGNX,negative
1005904.0,Mid-Morning Market Update: Markets Edge Lower; MassRoots Is Going To Leverage Blockchain For The Cannabis Industry,2017-12-29 10:11:00-05:00,PGNX,negative
1005905.0,Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA,2017-12-29 08:30:00-05:00,PGNX,positive
1005906.0,"Progenics Pharma Q3 EPS $(0.22) vs $(0.23) Est., Sales $2.56M vs $3.52M Est.",2017-11-02 08:12:00-04:00,PGNX,neutral
1005907.0,Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA in Pheochromocytoma and Paraganglioma,2017-11-02 07:48:00-04:00,PGNX,neutral
1005908.0,Progenics Pharmaceuticals Completes Submission of NDA for AZEDRAÂ® (iobenguane I 131) in Pheochromocytoma and Paraganglioma,2017-11-02 07:46:00-04:00,PGNX,neutral
1005909.0,Progenics Pharmaceuticals Reports Presentations on AZEDRA and its Prostate Cancer Programs at the 30th Annual Congress of the European Association of Nuclear Medicine,2017-10-16 16:31:00-04:00,PGNX,negative
1005910.0,12 Biggest Mid-Day Gainers For Monday,2017-09-18 12:29:00-04:00,PGNX,neutral
1005911.0,12 Biggest Mid-Day Losers For Friday,2017-09-01 13:14:00-04:00,PGNX,negative
1005912.0,Mid-Day Market Update: Palo Alto Networks Surges After Strong Q4 Results; Ambarella Shares Plunge,2017-09-01 12:00:00-04:00,PGNX,positive
1005913.0,UPDATE: Progenics Says 'Manufacturer Has Requested Additional Time to Prepare for Pre-Approval Inspection of the Manufacturing Site',2017-08-31 16:13:00-04:00,PGNX,neutral
1005914.0,Progenics Pharma Offers Update On Timing Of NDA Submission For AZEDRA: All Submissions Submitted Except For Notification Of Pre-Approval Inspection Readiness,2017-08-31 16:12:00-04:00,PGNX,positive
1005915.0,Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge,2017-08-28 14:30:00-04:00,PGNX,positive
1005916.0,"Progenics Pharma Reports Q2 EPS $(0.24) vs $(0.21) Est., Sales $2.765M vs $3.7M Est.",2017-08-09 07:40:00-04:00,PGNX,neutral
1005917.0,Watching Valeant Shares Following Filing From Progenics Showing Paragraph IV Certification Notification For Certain Patents For Subcutaneous RELISTOR,2017-07-18 16:54:00-04:00,PGNX,positive
1005918.0,8-K From Progenics Pharma Shows Co. Received Notification Of Paragraph IV Certification For Certain Patents For Subcutaneous RELISTOR,2017-07-18 16:53:00-04:00,PGNX,positive
1005919.0,"Progenics Shares Could Double, According To Cantor",2017-07-12 15:58:00-04:00,PGNX,positive
1005920.0,"Benzinga's Top Upgrades, Downgrades For July 12, 2017",2017-07-12 09:23:00-04:00,PGNX,positive
1005921.0,"Cantor Fitzgerald Initiates Coverage On Progenics Pharmaceuticals with Overweight Rating, Announces $15.00 Price Target",2017-07-12 07:09:00-04:00,PGNX,negative
1005922.0,Mid-Morning Market Update: Markets Open Mixed; Cognizant Earnings Beat Views,2017-05-05 10:07:00-04:00,PGNX,neutral
1005923.0,"Progenics Pharmaceuticals Reports Q1 EPS $(0.23) vs $(0.19) Est., Sales $2.34M vs $4.4M Est.",2017-05-04 08:12:00-04:00,PGNX,neutral
1005924.0,"Exclusive: Progenics CEO Talks Regulatory Climate, Positive Trials For Ultra-Orphan Azedra",2017-04-03 14:58:00-04:00,PGNX,positive
1005925.0,Progenics Pharma Reports Topline Results from Registrational Phase 2b Trial of AZEDRA: Achieved Primary Endpoint,2017-03-30 06:06:00-04:00,PGNX,neutral
1005926.0,Watch These 10 Huge Call Purchases In Tuesday Trade,2017-03-28 04:11:00-04:00,PGNX,positive
1005927.0,Benzinga's Option Alert Recap From March 27,2017-03-27 16:49:00-04:00,PGNX,positive
1005928.0,Option Alert: Progenics Pharma May 11.0 Calls Sweep: 500 @  ASK  $1.10: 500 traded vs 1387 OI:  Earnings 5/4 Before Open (est)  $10.98 Ref,2017-03-27 11:40:00-04:00,PGNX,positive
1005929.0,Benzinga's Option Alert Recap From March 24,2017-03-24 16:15:00-04:00,PGNX,positive
1005930.0,Option Alert: Progenics Pharma Apr 11.0 Calls: 550 @  ASK  $1.15: 1023 traded vs 1809 OI:  Earnings 5/4 Before Open (est)  $11.23 Ref,2017-03-24 13:26:00-04:00,PGNX,positive
1005931.0,"Progenics Pharmaceuticals Reports Q4 EPS $(0.10) vs. $(0.20) Est., Sales $4.65M vs. $4.81M Est.",2017-03-09 07:32:00-05:00,PGNX,neutral
1005932.0,"S&P Dow Jones Indices Reports Progenics Pharma, Shutterfly to Join S&P SmallCap 600",2017-02-15 17:56:00-05:00,PGNX,positive
1005933.0,Watch These 5 Huge Put Purchases In Wednesday Trade,2017-02-15 04:24:00-05:00,PGNX,positive
1005934.0,Option Alert: Progenics May 10.0 Puts Sweep: 500 @  ASK  $1.60: 500 traded vs 62 OI:  Earnings 3/9 Before Open (est)  $9.52 Ref,2017-02-14 11:50:00-05:00,PGNX,positive
1005935.0,Progenics Reports Initiation of Phase 1 Trial of 1095 for Treatment of Metastatic Prostate Cancer,2017-02-14 07:10:00-05:00,PGNX,negative
1005936.0,7 Biggest Price Target Changes For Monday,2017-02-06 09:57:00-05:00,PGNX,neutral
1005937.0,"Needham Upgrades Progenics Pharmaceuticals To Strong Buy, Raises Price Target To $14",2017-02-06 07:43:00-05:00,PGNX,positive
1005938.0,Progenics Pharma Files $250M Mixed Shelf,2017-01-09 06:28:00-05:00,PGNX,neutral
1005939.0,UPDATE: Progenics Says A Modification To Its Phase 3 SPECT/CT Trial Protocal Has Been Proposed To And Accepted By The FDA,2016-12-22 16:17:00-05:00,PGNX,positive
1005940.0,Progenics Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT,2016-12-22 16:16:00-05:00,PGNX,positive
1005941.0,Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL,2016-12-07 08:32:00-05:00,PGNX,neutral
1005942.0,Jefferies London Health Care Conference Continues Today,2016-11-17 10:14:00-05:00,PGNX,positive
1005943.0,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",2016-11-09 09:41:00-05:00,PGNX,neutral
1005944.0,"Progenics Pharma Reports Q3 EPS $0.52 vs $0.55 Est., Sales $53.85M vs $52.9M Est.",2016-11-07 07:56:00-05:00,PGNX,neutral
1005945.0,Progenics Pharma Reports $50M RELISTOR Royalty-Backed Financing,2016-11-07 07:53:00-05:00,PGNX,neutral
1005946.0,"Progenics Pharmaceuticals Received Notification Of Paragraph IV Certification For Certain Patents On Relistor Tablets, Listed In FDA's Orange Book",2016-10-28 16:34:00-04:00,PGNX,positive
1005947.0,Benzinga's Top Initiations,2016-10-27 09:35:00-04:00,PGNX,positive
1005948.0,"Aegis Capital Initiates Coverage On Progenics Pharmaceuticals Inc. - Common Stock at Buy, Announces $11.00",2016-10-27 05:51:00-04:00,PGNX,neutral
1005949.0,17 Stocks Which Rallied Three Days On Increasing Volume,2016-10-05 08:44:00-04:00,PGNX,neutral
1005950.0,"Brean Capital Assumes Progenics Pharmaceuticals at Buy, Announces $11.00 PT",2016-10-04 05:59:00-04:00,PGNX,neutral
1005951.0,"UPDATE: Also Watching Seres, Protagonist Therapeutics, Progenics Following Breaking 911 Report on 'Newest superbug'; Shares Not Reacting",2016-09-09 11:49:00-04:00,PGNX,positive
1005952.0,18 Biggest Mid-Day Gainers For Wednesday,2016-09-07 12:58:00-04:00,PGNX,neutral
1005953.0,22 Stocks Moving In Wednesday's Pre-Market Session,2016-09-07 08:28:00-04:00,PGNX,neutral
1005954.0,Progenics Spikes to High of $6.97 After-Hours on Relistor News,2016-09-06 17:02:00-04:00,PGNX,neutral
1005955.0,"Valeant, Progenics Reports The U.S. Commercial Launch Of FDA-Approved Relistor Tablets",2016-09-06 17:01:00-04:00,PGNX,neutral
1005956.0,Watch These 7 Huge Put Purchases In Thursday Trade,2016-08-25 03:44:00-04:00,PGNX,positive
1005957.0,Option Alert: PGNX Oct16 6.0 Puts Sweep: 500 @  ASK  $0.30: 500 traded vs 0 OI: $6.65 Ref,2016-08-24 15:03:00-04:00,PGNX,positive
1005958.0,"Progenics Pharmaceuticals Reports Q2 EPS $(0.08) vs. Est. $(0.13), Rev. $8.47M vs. Est. $6.33M",2016-08-04 07:55:00-04:00,PGNX,neutral
1005959.0,UPDATE: Progenics Also Entitled to Receive Up to $200M of Sales Milestone Payments Based on Specified US Sales Targets,2016-07-26 08:34:00-04:00,PGNX,positive
1005960.0,Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR,2016-07-26 08:30:00-04:00,PGNX,positive
1005961.0,Mid-Afternoon Market Update: NASDAQ Up Over 1%; Cintas Shares Surge On Upbeat Earnings,2016-07-20 14:44:00-04:00,PGNX,positive
1005962.0,Technical Alert - Progenics Pharmaceuticals Peaks At Mid-December Highs,2016-07-20 14:28:00-04:00,PGNX,positive
1005963.0,15 Biggest Mid-Day Gainers For Wednesday,2016-07-20 12:44:00-04:00,PGNX,neutral
1005964.0,Mid-Day Market Update: Microsoft Gains Following Earnings Beat; Zafgen Shares Slide,2016-07-20 12:19:00-04:00,PGNX,positive
1005965.0,Option Alert: PGNX 11500 Aug $6 Call at Bid @$0.55,2016-07-20 09:53:00-04:00,PGNX,positive
1005966.0,Mid-Morning Market Update: Markets Open Higher; Morgan Stanley Beats Q2 Estimates,2016-07-20 09:51:00-04:00,PGNX,neutral
1005967.0,15 Stocks Moving In Wednesday's Pre-Market Session,2016-07-20 08:21:00-04:00,PGNX,neutral
1005968.0,Progenics Pharmaceuticals +33% Preamarket @$6.59; Co Announced FDA Approval of Relistor Tablets for Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain,2016-07-20 06:19:00-04:00,PGNX,negative
1005969.0,Progenics Pharmaceuticals Resumes Trading; High of $6.50 +29%,2016-07-19 18:26:00-04:00,PGNX,neutral
1005970.0,Progenics Pharmaceuticals to Resume Trading at 6:25 PM ET,2016-07-19 18:11:00-04:00,PGNX,neutral
1005971.0,"Progenics Pharmaceuticals, Inc. Shares Up 11% At $5.49/Share After Hours",2016-07-19 18:06:00-04:00,PGNX,positive
1005972.0,"Valeant, Progenics Reports FDA Approves RELISTOR Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain",2016-07-19 18:05:00-04:00,PGNX,negative
1005973.0,Progenics Pharma Sells off to Low of $4.84 on Vol,2016-07-14 12:25:00-04:00,PGNX,negative
1005974.0,"Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform",2016-06-21 08:30:00-04:00,PGNX,positive
1005975.0,Progenics Licenses PSMA Antibody Technology to Bayer; Progenics lo Receive Upfront Fee Plus Additional Potential Clinical and Regulatory Development Milestones,2016-05-02 08:58:00-04:00,PGNX,neutral
1005976.0,"Valeant, Progenics Reports PDUFA Date Extension for Oral RELISTOR; Extended To July 19, 2016",2016-04-04 07:05:00-04:00,PGNX,neutral
1005977.0,Option Alert: PGNX Apr16 3.0 Puts: 500 @  ASK  $0.05: 500 traded vs 0 OI:  Earnings 5/4  $3.92 Ref,2016-03-17 09:51:00-04:00,PGNX,positive
1005978.0,Progenics Pharma. Reports Q4 EPS $(0.10) vs. Prior Year Quarter $(0.18),2016-03-11 08:01:00-05:00,PGNX,neutral
1005979.0,"Earnings Scheduled For March 11, 2016",2016-03-11 04:07:00-05:00,PGNX,neutral
1005980.0,Mid-Day Market Update: Akamai Technologies Surges On Earnings Beat; KapStone Paper and Packaging Shares Drop,2016-02-10 12:04:00-05:00,PGNX,neutral
1005981.0,"Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside",2016-01-12 10:45:00-05:00,PGNX,negative
1005982.0,Progenics Pharma Reports Commencement of Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer,2016-01-07 08:32:00-05:00,PGNX,negative
1005983.0,16 Stocks Moving In Friday's After-Hours Session,2015-12-11 17:03:00-05:00,PGNX,neutral
1005984.0,Progenics Pharmaceuticals Reaches Target Enrollment in its Phase 2b Pivotal Trial of Azedra,2015-12-03 08:31:00-05:00,PGNX,positive
1005985.0,"Progenics Pharma Reports Q3 EPS ($0.14) Vs Est ($0.13), Sales $1.4M Vs Est $2.35M",2015-11-09 07:30:00-05:00,PGNX,neutral
1005986.0,Benzinga's Top Upgrades,2015-10-23 09:21:00-04:00,PGNX,positive
1005987.0,"Jefferies Upgrades Progenics Pharmaceuticals to Buy, Raises PT to $9.00",2015-10-23 07:36:00-04:00,PGNX,neutral
1005988.0,Progenics Pharma 8-K Says Company Received Notice Of Paragraph IV Certification For Certain Patents For RELISTOR On Oct 7,2015-10-13 16:53:00-04:00,PGNX,positive
1005989.0,"Progenics Announces Offer to Acquire EXINI, $7M Cash",2015-10-13 08:01:00-04:00,PGNX,neutral
1005990.0,Progenics Pharmaceuticals Announces Tender Offer for Exini for 3.15 Swedish Crowns/Share -Reuters,2015-10-13 07:49:00-04:00,PGNX,neutral
1005991.0,Data From Phase 2 Study of Progenics' 1404 Imaging Agent Presented at EANM Congress 2015,2015-10-12 08:00:00-04:00,PGNX,neutral
1005992.0,"Valeant, Progenics Report FDA Acceptance Of NDA Submission For Oral RELISTOR",2015-09-08 08:02:00-04:00,PGNX,positive
1005993.0,"Progenics Pharma Reports Q2 Loss of $0.17/Share vs Loss of $0.14/Share Est., Sales $1.9M vs $1.63M Est.",2015-08-06 07:38:00-04:00,PGNX,negative
1005994.0,Progenics Pharmaceuticals Reports Exclusive Worldwide Licensing Agreement With Johns Hopkins University for Agent to Image Prostate Cancer Using PET Scan,2015-08-04 08:32:00-04:00,PGNX,negative
1005995.0,Mid-Morning Market Update: Markets Rise; Ford Beats Q2 Estimates,2015-07-28 10:37:00-04:00,PGNX,neutral
1005996.0,Stocks Hitting 52-Week Highs,2015-07-28 10:08:00-04:00,PGNX,neutral
1005997.0,Morning Market Gainers,2015-07-28 09:43:00-04:00,PGNX,neutral
1005998.0,"Azedra Designated as Breakthrough Therapy for Iobenguane-Avid Metastatic or Recurrent Pheochromocytoma and Paraganglioma, Received Orphan Drug And Fast Track Designations From FDA",2015-07-28 08:33:00-04:00,PGNX,neutral
1005999.0,Progenics Pharmaceuticals Reports Plans to Move Forward With 1404 Phase 3 Trial; Expects Trial To Commence By End of Year,2015-07-07 08:31:00-04:00,PGNX,neutral
1006000.0,Needham Is Bullish On Progenics Pharmaceuticals,2015-06-25 16:26:00-04:00,PGNX,neutral
1006001.0,Valeant and Progenics Submit U.S. New Drug Application for Oral RELISTOR,2015-06-23 09:19:00-04:00,PGNX,neutral
1006002.0,UPDATE: Progenics Shares +27%,2015-06-22 13:50:00-04:00,PGNX,positive
1006003.0,Progenics Pharma Shares Spike to New High,2015-06-22 12:10:00-04:00,PGNX,positive
1006004.0,Valeant Product Producer Progenics Announce European Approval For RELISTOR To Treat All Opioid Induced Constipation,2015-06-03 07:50:00-04:00,PGNX,positive
1006005.0,"BTIG Research Initiates Coverage on Progenics Pharmaceuticals at Buy, Announces $12.00 PT",2015-05-27 09:19:00-04:00,PGNX,neutral
1006006.0,Progenic Pharma Reports Q1 EPS Loss $0.15 Vs Est Loss $0.16,2015-05-06 08:01:00-04:00,PGNX,negative
1006007.0,Progenics Announces the Start of Fuji's Phase 2 Trial for 1404 in Japan,2015-04-07 08:32:00-04:00,PGNX,neutral
1006008.0,Progenics Pharma Reports Q4 EPS -$0.18 Vs Est -$0.13,2015-03-16 08:01:00-04:00,PGNX,neutral
1006009.0,"Earnings Scheduled For March 16, 2015",2015-03-16 04:34:00-04:00,PGNX,neutral
1006010.0,"UPDATE: Progenics Says Data from Trial Provides Compelling Evidence of Anti-Cancer Properties of PSMA ADC""",2015-02-26 11:32:00-05:00,PGNX,positive
1006011.0,Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA,2015-01-23 08:09:00-05:00,PGNX,neutral
1006012.0,Morning Market Movers ,2014-11-07 09:42:00-05:00,PGNX,neutral
1006013.0,Progenics Shares Rise 19% Premarket on Much Better than Expected Earnings Report,2014-11-07 08:24:00-05:00,PGNX,positive
1006014.0,Progenics Pharmaceuticals Inc. Reports Q3 EPS of $0.51; Revenue of $41.70M,2014-11-07 08:01:00-05:00,PGNX,neutral
1006015.0,"Earnings Scheduled For November 7, 2014",2014-11-07 05:13:00-05:00,PGNX,neutral
1006016.0,Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress,2014-10-20 08:04:00-04:00,PGNX,neutral
1006017.0,UPDATE: Progenics Shares Rise 25% Following CNBC Mention,2014-10-16 08:22:00-04:00,PGNX,positive
1006018.0,Progenix Mentioned on CNBC as Ebola Play,2014-10-16 08:21:00-04:00,PGNX,positive
1006019.0,Progenics Receives $40M Milestone Following FDA Approval of RELISTOR For OIC Patients With Chronic Non-Cancer Pain,2014-10-06 16:31:00-04:00,PGNX,negative
1006020.0,Morning Market Losers ,2014-09-30 09:51:00-04:00,PGNX,negative
1006021.0,"Progenics Shares Resume Trading, Now Up 3.5%",2014-09-29 18:09:00-04:00,PGNX,positive
1006022.0,"UPDATE: Salix, Progenics Report FDA Okay of RELISTOR",2014-09-29 17:31:00-04:00,PGNX,positive
1006023.0,"Salix, Progenics Report FDA Okay of RELISTOR",2014-09-29 17:30:00-04:00,PGNX,positive
1006024.0,Shares of Progenics Halted News Pending,2014-09-29 17:04:00-04:00,PGNX,positive
1006025.0,"Jefferies Initiates Coverage on Progenics Pharmaceuticals Inc. at Hold, Announces $6.00 PT",2014-09-23 06:04:00-04:00,PGNX,neutral
1006026.0,US Stock Futures Signal Higher Start On Wall Street,2014-08-11 07:44:00-04:00,PGNX,neutral
1006027.0,"FDA Assigns September 29, 2014 PDUFA Goal Date for RELISTOR Subcutaneous Injection sNDA ",2014-08-11 07:13:00-04:00,PGNX,neutral
1006028.0,Progenics Pharmaceuticals Inc. Reports Q2 EPS of $(0.17) vs $(0.14) Est; Revenue of $1.48M vs $2.83M Est,2014-08-08 08:06:00-04:00,PGNX,neutral
1006029.0,"Earnings Scheduled For August 8, 2014",2014-08-08 05:22:00-04:00,PGNX,neutral
1006030.0,Morning Market Movers ,2014-07-14 09:38:00-04:00,PGNX,neutral
1006031.0,Benzinga's Top #PreMarket Gainers,2014-07-14 08:10:00-04:00,PGNX,positive
1006032.0,Progenics Pharma Shares up ~18%,2014-07-14 07:34:00-04:00,PGNX,positive
1006033.0,US Stock Futures Surge; All Eyes On Citigroup Results,2014-07-14 07:29:00-04:00,PGNX,neutral
1006034.0,PREVIEW: Progenics Pharmaceuticals to Resume Trading at 7:30 AM ET,2014-07-14 07:08:00-04:00,PGNX,neutral
1006035.0,"UPDATE: Salix, Progenics Report FDA Office Of Drug Evaluation III Approves Salix Request For FDA Approval Of RELISTOR sNDA",2014-07-14 07:06:00-04:00,PGNX,positive
1006036.0,Progenics Announces Will Host Call Related to FDA Appeal Response Related to RELISTOR sNDA,2014-07-14 07:06:00-04:00,PGNX,neutral
1006037.0,"Salix, Progenics Report FDA Office of Drug Evaluation III Approves Salix Request for FDA Approval of RELISTOR sNDA",2014-07-14 07:02:00-04:00,PGNX,positive
1006038.0,Progenics Pharmaceuticals Halted; Pending News,2014-07-14 06:56:00-04:00,PGNX,neutral
1006039.0,"Shares of Progenics Resume Trade, Now Up Nearly 19%",2014-06-12 15:16:00-04:00,PGNX,positive
1006040.0,Shares of Progenics to Resume Trade at 3:15 p.m. EDT,2014-06-12 15:13:00-04:00,PGNX,positive
1006041.0,Sucampo Says FDA Did Not Require Company To Reevaluate Clinical Data Because Action Mechanism For Opiod Constipation is Different,2014-06-12 14:45:00-04:00,PGNX,neutral
1006042.0,"Salix Pharma, Progenics Pharma Report on FDA Advisory Panel Recommendations, 12 Members Voted Not to Require CVOT Trial, Sseven Vote to Require CVOT for Pamorsa",2014-06-12 14:34:00-04:00,PGNX,neutral
1006043.0,"Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday",2014-06-12 09:41:00-04:00,PGNX,neutral
1006044.0,"UPDATE: Nektar Therapeutics, Progenics Halted for FDA Advisory Committees",2014-06-11 07:07:00-04:00,PGNX,neutral
1006045.0,"Nektar Therapeutics, Progenics Halted: Pending News",2014-06-11 06:59:00-04:00,PGNX,neutral
1006046.0,Small Pharmaceuticals Rallying Following FDA Report,2014-06-09 12:49:00-04:00,PGNX,neutral
1006047.0,"Mid-Afternoon Market Update; Hertz Down, QuikSilver Gain On CEO & CFO Share Purchases",2014-06-06 15:01:00-04:00,PGNX,positive
1006048.0,Mid-Day Market Update: Diamond Foods Shares Fall After Weak Earnings; GW Pharma Gains,2014-06-06 12:37:00-04:00,PGNX,positive
1006049.0,"Progenics Pharmaceuticals Inc. Reports Q1 EPS of $(0.15), Inline; Revenue of $1.82M vs $2.88M Est",2014-05-09 07:32:00-04:00,PGNX,neutral
1006050.0,"Earnings Scheduled For May 9, 2014",2014-05-09 05:18:00-04:00,PGNX,neutral
1006051.0,Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC ,2014-04-24 10:17:00-04:00,PGNX,negative
1006052.0,US Stock Futures Edge Higher Ahead Of McDonald's Earnings,2014-04-22 07:31:00-04:00,PGNX,neutral
1006053.0,"Salix Pharma, Progenics Reports Acceptance of Submission for Expanded Use of RELISTOR in Chronic Non-Cancer Pain by EMA",2014-04-22 07:10:00-04:00,PGNX,negative
1006054.0,"Salix Pharmaceuticals, Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand Use of RELISTORby the European Medicines Agency",2014-04-22 07:02:00-04:00,PGNX,positive
1006055.0,Progenics Pharmaceuticals Inc. Reports Q4 EPS of $(0.14) vs $(0.19) Est; Revenue of $2.97M vs $1.48M Est,2014-03-13 07:39:00-04:00,PGNX,neutral
1006056.0,"Earnings Scheduled For March 13, 2014",2014-03-13 04:51:00-04:00,PGNX,neutral
1006057.0,"Progenics Prices 7.61M Shares at $4.60/Share, Expecting Gross Proceeds $35M",2014-02-21 09:00:00-05:00,PGNX,negative
1006058.0,"Option Alert: Progenics Mar $6 Call; 3,078 Contracts Traded vs 697 OI; Currently $4.55",2014-02-06 12:51:00-05:00,PGNX,positive
1006059.0,"Bloomberg Reporting Progenix, Salix Informed by FDA That ADPAC Meeting Postponed; FDA Cited Scheduling Conflicts",2014-02-06 12:48:00-05:00,PGNX,negative
1006060.0,"Needham Upgrades Progenics Pharmaceuticals Inc. to Buy, Announces $8.00 PT",2014-02-03 08:08:00-05:00,PGNX,neutral
1006061.0,UPDATE: Progenics Shares Rise 19% on Positive Phase 2 Study Resukts,2014-01-30 14:58:00-05:00,PGNX,positive
1006062.0,Progenics 1404 Imaging Agent Shows High Accuracy in Detecting Cancer Within the Prostate Gland in Interim Analysis of Phase 2 Study ,2014-01-30 14:32:00-05:00,PGNX,negative
1006063.0,Progenics Pharmaceuticals Presents Positive Data From a Phase 2 Trial of PSMA ADC in Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer ,2014-01-30 14:32:00-05:00,PGNX,negative
1006064.0,"Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors",2014-01-29 16:49:00-05:00,PGNX,neutral
1006065.0,"Option Alert: Progenics Pharmaceuticals Feb $5 Call; 1,671 Contract Trade Between Bid and Ask @$0.50; Currently $4.58",2014-01-29 14:55:00-05:00,PGNX,positive
1006066.0,Progenics Pharmaceuticals Relaunches Registrational Trial of Azedra to Treat Pheochromocytomas ,2013-11-25 05:59:00-05:00,PGNX,positive
1006067.0,Progenics Pharmaceuticals Inc. Reports Q3 EPS of $(0.17) vs $(0.22) Est; Revenue of $867.0K vs $2.0M Est,2013-11-11 07:31:00-05:00,PGNX,neutral
1006068.0,"Earnings Scheduled For November 11, 2013",2013-11-11 04:46:00-05:00,PGNX,neutral
1006069.0,Salix Says FDA Scheduled to Review Relistor SNDA March 10-11,2013-10-01 14:33:00-04:00,PGNX,neutral
1006070.0,"Progenics Pharmaceuticals Inc. Reports Q2 EPS of $(0.24), Inline; Revenue of $1.80M vs $1.86M Est",2013-08-09 07:30:00-04:00,PGNX,neutral
1006071.0,Afternoon Market Gainers ,2013-07-08 13:45:00-04:00,PGNX,neutral
1006072.0,"Brean Capital Upgrades Progenics Pharmaceuticals Inc. to Buy, Announces $9.00 PT",2013-07-08 08:31:00-04:00,PGNX,neutral
1006073.0,Form 8-K from Progenics Pharma Shows Co. Closed 8.5M Primary Share Offering,2013-06-25 13:00:00-04:00,PGNX,positive
1006074.0,Progenics Prices 8.5M Shares at $4.40/Share for Gross Proceeds $37.4M,2013-06-20 09:16:00-04:00,PGNX,negative
1006075.0,Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock ,2013-06-19 16:04:00-04:00,PGNX,neutral
1006076.0,Afternoon Market Gainers,2013-06-11 12:53:00-04:00,PGNX,neutral
1006077.0,Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain ,2013-06-11 09:02:00-04:00,PGNX,negative
1006078.0,Afternoon Market Losers,2013-06-10 14:16:00-04:00,PGNX,negative
1006079.0,Progenics Pharmaceuticals' Presents Data from Phase 1 Study of PSMA ADC ,2013-06-01 11:29:00-04:00,PGNX,neutral
1006080.0,Progenics Pharmaceuticals Inc. Reports Q1 EPS of $(0.22) vs $(0.19) Est; Revenue of $2.23M vs $1.71M Est,2013-05-10 07:32:00-04:00,PGNX,neutral
1006081.0,"Earnings Scheduled For May 10, 2013",2013-05-10 04:51:00-04:00,PGNX,neutral
1006082.0,"Benzinga's Small Cap Movers for Friday March 15, 2013",2013-03-17 11:34:00-04:00,PGNX,neutral
1006083.0,"Market Wrap for Friday, March 15: Dow Snaps Winning Streak; Stocks Record Minor Losses",2013-03-15 16:16:00-04:00,PGNX,positive
1006084.0,"Unusual Options Activity: Progenics Pharmaceuticals May $4.00 At-The-Money Puts Trade 5,170 Times Against an Open Interest of 8 After Company Reported Earnings This Morning",2013-03-15 13:39:00-04:00,PGNX,positive
1006085.0,Progenics Pharmaceuticals Inc. Reports Q4 EPS of $(0.01) Which May Not Compare $(0.31) Est; Revenue of $8.89M Which May Not Compare $1.16M Est,2013-03-15 07:43:00-04:00,PGNX,neutral
1006086.0,"Earnings Scheduled For March 15, 2013",2013-03-15 05:00:00-04:00,PGNX,neutral
1006087.0,"Stocks on my Watch List for Friday, December 21",2012-12-21 07:38:00-05:00,PGNX,neutral
1006088.0,Top Stocks on my Watch List for Thursday December 20th,2012-12-20 08:58:00-05:00,PGNX,positive
1006089.0,Progenics Pharma Says 11M Shares Priced at $2/Share,2012-11-29 09:07:00-05:00,PGNX,positive
1006090.0,Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients,2012-09-28 08:03:00-04:00,PGNX,negative
1006091.0,"Progenics Pharma Cutting 26% of Jobs, CFO Stepping Down",2012-09-20 16:03:00-04:00,PGNX,negative
1006092.0,Stifel Nicolaus Initiates Coverage on Progenics Pharmaceuticals at Hold,2012-08-30 08:04:00-04:00,PGNX,neutral
1006093.0,Progenics Pharmaceuticals Reports Q2 EPS $-0.32 vs $-0.32 Est; Revenues $1.82M vs $2.61M Est,2012-08-09 07:38:00-04:00,PGNX,neutral
1006094.0,Progenics Pharmaceuticals Reports Q2 EPS $-0.32 vs $-0.32 Est; Revenues $1.82M vs $2.61M Est,2012-08-09 07:33:00-04:00,PGNX,neutral
1006095.0,Benzinga's Top Pre-Market Losers,2012-07-30 08:22:00-04:00,PGNX,negative
1006096.0,"Financial Breakfast: Morning News Summary for July 30, 2012",2012-07-30 07:29:00-04:00,PGNX,neutral
1006097.0,"Salix Pharmaceuticals Falls 15%, Progenics Falls 40% Pre-Market Following Receipt of CRL from FDA",2012-07-30 07:21:00-04:00,PGNX,neutral
1006098.0,"Friday, Salix and Progenics Receive Complete Response Letter from FDA for RELISTOR(R) sNDA; FDA Requests More Data",2012-07-30 07:16:00-04:00,PGNX,neutral
1006099.0,"Brean Murray Carret & Co. Maintains Progenics Pharmaceuticals at Buy, Raises PT from $13 to $14",2012-03-15 11:14:00-04:00,PGNX,neutral
1006100.0,Investor Ideas' Tuesday's NASDAQ Winners,2011-12-21 13:15:00-05:00,PGNX,positive
1006101.0,"Microcap Movers for Tuesday December 20, 2011",2011-12-20 21:33:00-05:00,PGNX,neutral
1006102.0,Progenics Pharma Up 30% on Positive Phase 3 Results,2011-12-20 15:42:00-05:00,PGNX,positive
1006103.0,Notable Call Options Activity in Progenics Pharmaceuticals,2011-12-20 10:41:00-05:00,PGNX,neutral
1006104.0,Morning Market Movers,2011-12-20 09:51:00-05:00,PGNX,neutral
1006105.0,"Financial Breakfast: Morning News Summary for December 20, 2011",2011-12-20 07:27:00-05:00,PGNX,neutral
1006106.0,Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic,2011-12-20 07:06:00-05:00,PGNX,positive
1006107.0,Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar),2011-12-11 23:22:00-05:00,PGNX,neutral
1006108.0,Notable Call Options Activity in Progenics Pharmaceuticals,2011-12-07 11:22:00-05:00,PGNX,neutral
1006109.0,Progenics Pharmaceuticals Announces Strategic Focus on Oncology  ,2011-09-15 07:33:00-04:00,PGNX,neutral
1006110.0,Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR in Patients with Non-Cancer Pain   ,2011-08-30 07:02:00-04:00,PGNX,negative
1006111.0,Progenics Pharm Files $100 Mixed Securities Shelf,2011-08-11 17:02:00-04:00,PGNX,positive
1006112.0,"Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients",2011-05-20 08:03:00-04:00,PGNX,negative
1006113.0,Progenics Pharmaceuticals Hits 52-Week High (PGNX),2011-04-14 11:21:00-04:00,PGNX,neutral
1006114.0,Progenics Pharmaceuticals Reports Q4 EPs of $(0.57) vs. $(0.57),2011-03-15 08:13:00-04:00,PGNX,neutral
1006115.0,Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC   ,2011-02-17 16:50:00-05:00,PGNX,positive
1006116.0,"Benzinga's Top Pre-Market NASDAQ Gainers (WFMI, PGNX, SQNM, XNPT)",2011-02-10 08:26:00-05:00,PGNX,positive
1006117.0,"Benzinga's Top Pre-Market NASDAQ Gainers (OREX, PGNX, GOLD, GENZ)",2011-02-07 08:18:00-05:00,PGNX,positive
1006118.0,Progenics Pharmaceuticals Climbs 5.9% (PGNX),2010-12-23 15:35:00-05:00,PGNX,neutral
1006119.0,Progenics Pharmaceuticals Announces Third Quarter EPS of $(0.52),2010-11-08 08:06:00-05:00,PGNX,neutral
1006120.0,Progenics Awarded $4.1 Million NIH Grant ,2010-10-06 09:02:00-04:00,PGNX,positive
1006121.0,Traders Bullish on Progenics Pharma (PGNX),2010-09-22 12:08:00-04:00,PGNX,neutral
1006122.0,Oppenheimer's Current Biotech Ratings,2010-09-13 10:41:00-04:00,PGNX,neutral
1006123.0,"Trade Like Hedge Fund Billionaire Paul Tudor Jones (EEM, FXI, MJN, PGNX, RSX, XLP)",2010-08-12 13:12:00-04:00,PGNX,positive
1006124.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,PGNX,positive
